title: Have a high index of suspicion for atrial fibrillation.
abstract: The lifetime risk of atrial fibrillation (AF) for men and women over the age of 40 is about 25%. The condition affects around 800,000 people in the UK, of which it is estimated that 250,000 are undiagnosed. A rapid heart rate may result in palpitations, dyspnoea or chest tightness, whereas loss of atrial contractility may lead to fatigue and reduced exercise capacity. There is a five-fold increased risk of ischaemic stroke, transient ischaemic attack or systemic embolism. AF strokes are larger, more disabling and have a higher mortality rate than those with other causes. The risk of stroke is not related to the presence or absence of symptoms, or whether the AF is paroxysmal or persistent. When an irregular pulse is detected it should precipitate further assessment with a 12-lead ECG. In patients with intermittent palpitations that may represent AF, prolonged ECG monitoring can be used to increase the chance of diagnosis. In patients with a confirmed diagnosis of AF, three areas need to be considered, stroke risk, symptoms, and risk of tachycardia cardiomyopathy. The CHA2DS2-VASc score is used to assess the stroke risk in patients with AF. Oral anticoagulation should be offered to those with a CHA2DS2-VASc score of 2 or more, and considered for men with a score of 1. The risk of severe bleeding with warfarin should also be assessed using the HAS-BLED score. A score of 3 or more indicates that caution is required when starting any anticoagulant therapy. Oral anticoagulant therapy can reduce the risk of stroke by around 50-70%. It should be started when the patient reaches 65 or if he/she develops any of the risk factors for stroke.
authors.affiliation: Oxford Heart Centre, John Radcliffe Hospital, Oxford, UK.
authors.forename: Milena
authors.initials: M
authors.lastname: Leo
authors.forename: Tim
authors.initials: T
authors.lastname: Betts
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology / Q000523:psychology; D019468:Disease Management; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D002546:Ischemic Attack, Transient / Q000209:etiology / Q000517:prevention & control; D008297:Male; D017410:Practice Guidelines as Topic; D020379:Risk Adjustment; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D000925:Anticoagulants